Home

Welcome to NLS Pharmaceutics

We are seeking to design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity. We are seeking to create new approaches to treat mental and behavioral disorders, and to enhance cognitive function in healthy people.

Press Room

Interview with Alex Zwyer, CEO of NLS Pharmaceutics Ltd. (NLS) at The London Stock Exchange Studios. You can see more info of NLS Pharmaceutics on the media in our Press Room section

Latest News

  • Feb 25, 2021
    NLS Pharmaceutics to Participate in Upcoming Investor Conferences
  • Feb 2, 2021
    NLS Pharmaceutics Ltd. Announces Closing of $20.0 Million Initial Public Offering
  • Jan 28, 2021
    NLS Pharmaceutics Ltd. Announces Pricing of $20.0 Million Initial Public Offering
  • Jan 21, 2021
    NLS Pharmaceutics Ltd. Announces Notice of Allowance of a new Technology Patent Covering Attention Deficit Hyperactivity Disorder & Narcolepsy
Contact us

NLS Pharmaceutics is very interested in hearing from you. Please find general contact information below.

NLS PHARMACEUTICS GROUP
Alter Postplatz 2
CH-6370 Stans NW
Switzerland

T: +41 41 618 80 00
F: +41 41 618 80 09
askus@nls-pharma.com

Your Name (required)

Your Email (required)

Subject

Your Message